1
|
Liu L, Li Y, Zheng X, Huang R, Huang X, Zhao Y, Liu W, Lei Y, Li Q, Zhong Z, Zhao Z. Natural polysaccharides regulate intestinal microbiota for inhibiting colorectal cancer. Heliyon 2024; 10:e31514. [PMID: 38818184 PMCID: PMC11137569 DOI: 10.1016/j.heliyon.2024.e31514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2024] [Revised: 05/11/2024] [Accepted: 05/16/2024] [Indexed: 06/01/2024] Open
Abstract
The gastrointestinal tract is an important part of the human immune system. The gut microbiome, which constitutes a major component of the gastrointestinal tract, plays a crucial role in maintaining normal physiological functions and influences the development, diagnosis, and immunotherapy of colorectal cancer (CRC). Natural polysaccharides can be extracted from animals, plants, and traditional Chinese medicines. They serve as an essential energy source for the gut microbiome, promoting probiotic proliferation and regulating the intestinal microecological balance. Moreover, polysaccharides exhibit anti-tumor effects due to their immune regulatory functions and low toxicity. This review focuses on discussing these anti-tumor effects in CRC, along with improving gut microbiome dysbiosis and regulating the tumor immune microenvironment, providing evidence for effective therapeutic strategies against CRC.
Collapse
Affiliation(s)
- Lili Liu
- University of Health and Rehabilitation Sciences (Qingdao Central Medical Group), Qingdao, 266000, China
| | - Yinan Li
- University of Health and Rehabilitation Sciences (Qingdao Central Medical Group), Qingdao, 266000, China
| | - Xiaoting Zheng
- Macao Centre for Research and Development in Chinese Medicine, State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, 999078, China
| | - Rong Huang
- Macao Centre for Research and Development in Chinese Medicine, State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, 999078, China
- College of Chemistry and Pharmaceutical Sciences, National Joint Local Engineering Laboratory of Agricultural Bio-Pharmaceutical Laboratory, Qingdao, Agricultural University, Qingdao, 266109, China
| | - Xiaoli Huang
- College of Chemistry and Pharmaceutical Sciences, National Joint Local Engineering Laboratory of Agricultural Bio-Pharmaceutical Laboratory, Qingdao, Agricultural University, Qingdao, 266109, China
| | - Yonghui Zhao
- University of Health and Rehabilitation Sciences (Qingdao Central Medical Group), Qingdao, 266000, China
| | - Wenjing Liu
- College of Chemistry and Pharmaceutical Sciences, National Joint Local Engineering Laboratory of Agricultural Bio-Pharmaceutical Laboratory, Qingdao, Agricultural University, Qingdao, 266109, China
| | - Yanli Lei
- College of Chemistry and Pharmaceutical Sciences, National Joint Local Engineering Laboratory of Agricultural Bio-Pharmaceutical Laboratory, Qingdao, Agricultural University, Qingdao, 266109, China
| | - Qiu Li
- College of Chemistry and Pharmaceutical Sciences, National Joint Local Engineering Laboratory of Agricultural Bio-Pharmaceutical Laboratory, Qingdao, Agricultural University, Qingdao, 266109, China
| | - Zhangfeng Zhong
- Macao Centre for Research and Development in Chinese Medicine, State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, 999078, China
| | - Ziyun Zhao
- University of Health and Rehabilitation Sciences (Qingdao Central Medical Group), Qingdao, 266000, China
| |
Collapse
|
2
|
Chen W, Hu Z, Guo Z. Targeting CD24 in Cancer Immunotherapy. Biomedicines 2023; 11:3159. [PMID: 38137380 PMCID: PMC10740697 DOI: 10.3390/biomedicines11123159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2023] [Revised: 11/19/2023] [Accepted: 11/22/2023] [Indexed: 12/24/2023] Open
Abstract
Immunotherapy is a hot area in cancer treatment, and one of the keys to this therapy is the identification of the right tumour-associated or tumour-specific antigen. Cluster of differentiation 24 (CD24) is an emerging tumour-associated antigen that is commonly and highly expressed in various tumours. In addition, CD24 is associated with several cancer-related signalling pathways and closely interacts with other molecules and immune cells to influence tumour progression. Monoclonal antibodies, antibody-drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell therapy, and CAR-NK cell therapy are currently available for the treatment of CD24. In this review, we summarise the existing therapeutic approaches and possible future directions targeting CD24.
Collapse
Affiliation(s)
| | - Zhigang Hu
- Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, 1 Wenyuan Road, Nanjing 210023, China;
| | - Zhigang Guo
- Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, 1 Wenyuan Road, Nanjing 210023, China;
| |
Collapse
|
3
|
Yang Y, Zhu G, Yang L, Yang Y. Targeting CD24 as a novel immunotherapy for solid cancers. Cell Commun Signal 2023; 21:312. [PMID: 37919766 PMCID: PMC10623753 DOI: 10.1186/s12964-023-01315-w] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2023] [Accepted: 09/13/2023] [Indexed: 11/04/2023] Open
Abstract
Cluster of differentiation 24 (CD24), a mucin-like highly glycosylated molecule has been extensively studied as a cancer stem cell marker in a variety of solid cancers. The functional role of CD24 is either fulfilled by combining with ligands or participating in signal transduction, which mediate the initiation and progression of neoplasms. Recently, CD24 was also described as an innate immune checkpoint with apparent significance in several types of solid cancers. Herein, we review the current understanding of the molecular fundamentals of CD24, the role of CD24 in tumorigenesis and cancer progression, the possibility as a promising therapeutic target and summarized different therapeutic agents or strategies targeting CD24 in solid cancers. Video Abstract.
Collapse
Affiliation(s)
- Yan Yang
- Xinxiang Engineering Technology Research Center of Tumor-Targeted Drug Development, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, 453000, Henan, China
| | - Guangming Zhu
- Clinical Laboratory, The First People's Hospital of Taian, Taian 271000, Shandong, China
| | - Li Yang
- Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou Key Laboratory of Endometrial Disease Prevention and Treatment Zhengzhou China, Zhengzhou, 450052, Henan, China
| | - Yun Yang
- Xinxiang Engineering Technology Research Center of Tumor-Targeted Drug Development, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, 453000, Henan, China.
| |
Collapse
|